Biofrontera is a biopharmaceutical company focusing on commercialization of pharmaceutical products. Co.'s principal product is Ameluz®, which is a prescription drug approved for use in combination with its licensor's medical device, which has been approved by the U.S. Food and Drug Administration, the BF-RhodoLED® lamp, for photodynamic therapy, or PDT, (when used together, Ameluz® PDT) in the U.S. for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. Co.'s second prescription drug product in its portfolio is Xepi® (ozenoxacin cream, 1%), a topical non-fluorinated quinolone that inhibits bacterial growth. The BFRI YTD return is shown above.
The YTD Return on the BFRI YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether BFRI YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BFRI YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|